Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.36
CLSN's Cash to Debt is ranked lower than
68% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. CLSN: 3.36 )
Ranked among companies with meaningful Cash to Debt only.
CLSN' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 3.36

Equity to Asset 0.45
CLSN's Equity to Asset is ranked lower than
73% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLSN: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
CLSN' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.97
Current: 0.45

-1.05
0.97
F-Score: 2
Z-Score: -4.78
M-Score: 4.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5185.20
CLSN's Operating margin (%) is ranked lower than
89% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. CLSN: -5185.20 )
Ranked among companies with meaningful Operating margin (%) only.
CLSN' s 10-Year Operating margin (%) Range
Min: -163200   Max: -75.32
Current: -5185.2

-163200
-75.32
Net-margin (%) -5415.20
CLSN's Net-margin (%) is ranked lower than
89% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. CLSN: -5415.20 )
Ranked among companies with meaningful Net-margin (%) only.
CLSN' s 10-Year Net-margin (%) Range
Min: -151566.67   Max: -67.41
Current: -5415.2

-151566.67
-67.41
ROE (%) -73.43
CLSN's ROE (%) is ranked lower than
74% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. CLSN: -73.43 )
Ranked among companies with meaningful ROE (%) only.
CLSN' s 10-Year ROE (%) Range
Min: -6771.43   Max: 257.55
Current: -73.43

-6771.43
257.55
ROA (%) -40.49
CLSN's ROA (%) is ranked lower than
64% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. CLSN: -40.49 )
Ranked among companies with meaningful ROA (%) only.
CLSN' s 10-Year ROA (%) Range
Min: -727.9   Max: 121.96
Current: -40.49

-727.9
121.96
ROC (Joel Greenblatt) (%) -2635.83
CLSN's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CLSN: -2635.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLSN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15483.87   Max: -114.68
Current: -2635.83

-15483.87
-114.68
Revenue Growth (3Y)(%) -58.80
CLSN's Revenue Growth (3Y)(%) is ranked lower than
87% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. CLSN: -58.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLSN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -27.1
Current: -58.8

EBITDA Growth (3Y)(%) -35.70
CLSN's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CLSN: -35.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLSN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -57.5   Max: 39.1
Current: -35.7

-57.5
39.1
EPS Growth (3Y)(%) -34.90
CLSN's EPS Growth (3Y)(%) is ranked lower than
83% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CLSN: -34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLSN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.2   Max: 30.5
Current: -34.9

-48.2
30.5
» CLSN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CLSN Guru Trades in Q2 2014

Chuck Royce 233,159 sh (unchged)
» More
Q3 2014

CLSN Guru Trades in Q3 2014

Jim Simons 49,964 sh (New)
Chuck Royce 233,159 sh (unchged)
» More
Q4 2014

CLSN Guru Trades in Q4 2014

Jim Simons 116,486 sh (+133.14%)
Chuck Royce 233,159 sh (unchged)
» More
Q1 2015

CLSN Guru Trades in Q1 2015

Chuck Royce 213,159 sh (-8.58%)
Jim Simons 41,637 sh (-64.26%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
CLSN's P/B is ranked higher than
84% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CLSN: 1.90 )
Ranked among companies with meaningful P/B only.
CLSN' s 10-Year P/B Range
Min: 1.25   Max: 170.59
Current: 1.9

1.25
170.59
P/S 98.05
CLSN's P/S is ranked lower than
88% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. CLSN: 98.05 )
Ranked among companies with meaningful P/S only.
CLSN' s 10-Year P/S Range
Min: 2.24   Max: 760.5
Current: 98.05

2.24
760.5
Current Ratio 2.98
CLSN's Current Ratio is ranked lower than
62% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CLSN: 2.98 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s 10-Year Current Ratio Range
Min: 0.3   Max: 104.65
Current: 2.98

0.3
104.65
Quick Ratio 2.98
CLSN's Quick Ratio is ranked lower than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CLSN: 2.98 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s 10-Year Quick Ratio Range
Min: 0.3   Max: 104.65
Current: 2.98

0.3
104.65
Days Sales Outstanding 27.74
CLSN's Days Sales Outstanding is ranked higher than
81% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. CLSN: 27.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLSN' s 10-Year Days Sales Outstanding Range
Min: 4.2   Max: 2190
Current: 27.74

4.2
2190

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.00
CLSN's Price/Tangible Book is ranked higher than
87% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CLSN: 2.00 )
Ranked among companies with meaningful Price/Tangible Book only.
CLSN' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 222.75
Current: 2

1.05
222.75
Price/Median PS Value 3.30
CLSN's Price/Median PS Value is ranked lower than
81% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CLSN: 3.30 )
Ranked among companies with meaningful Price/Median PS Value only.
CLSN' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 108.7
Current: 3.3

0.14
108.7
Earnings Yield (Greenblatt) -85.40
CLSN's Earnings Yield (Greenblatt) is ranked lower than
97% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CLSN: -85.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CLSN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -291.7   Max: 771.8
Current: -85.4

-291.7
771.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a Delaware corporation incorporated in 1982. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Reports Second Quarter 2009 Financial Results and Business Update Aug 05 2009 
Celsion to Hold Second Quarter 2009 Financial Results Jul 31 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 
Celsion Corporation to Hold Conference Call to Discuss Its Announced Japan License Agreement for The Dec 16 2008 
Celsion Corporation Announces Exclusive Japan License Agreement with Yakult Honsha for ThermoDox® Dec 15 2008 

More From Other Websites
Celsion Presents GEN-1 Immunotherapy Phase 1b Results in Recurrent Ovarian Cancer at ASCO 2015 Jun 01 2015
8:04 am Celsion presents GEN-1 immunotherapy Phase 1b results in recurrent ovarian cancer at ASCO... Jun 01 2015
Celsion Presents GEN-1 Immunotherapy Phase 1b Results in Recurrent Ovarian Cancer at ASCO 2015 Jun 01 2015
CELSION CORP Files SEC form 8-K/A, Financial Statements and Exhibits May 29 2015
CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 28 2015
Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering May 28 2015
Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering May 28 2015
Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence™ RNA... May 21 2015
Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence™ RNA... May 21 2015
CELSION CORP Financials May 19 2015
Celsion Announces Publication of Preclinical Data Demonstrating Lung Specific Delivery of... May 15 2015
Celsion Announces Publication of Preclinical Data Demonstrating Lung Specific Delivery of... May 15 2015
10-Q for Celsion Corp. May 13 2015
Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer... May 13 2015
Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer... May 13 2015
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 12 2015
Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update May 12 2015
Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update May 12 2015
Q1 2015 Celsion Corp Earnings Release - Before Market Open May 12 2015
CELSION CORP Files SEC form 10-Q, Quarterly Report May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK